Hypofractionation for clinically localized prostate cancer.

CONCLUSIONS: These findings suggest that moderate hypofractionation (up to a fraction size of 3.4 Gy) results in similar oncologic outcomes in terms of disease-specific, metastasis-free and overall survival. There appears to be little to no increase in both acute and late toxicity. PMID: 31476800 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31476800?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - September 2, 2019 Category: General Medicine Authors: Hickey BE, James ML, Daly T, Soh FY, Jeffery M Tags: Cochrane Database Syst Rev Source Type: research